MASH

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

2026-02-25

F. Hoffmann-La Roche Ltd 89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated…

RRoche

MASH dash speeds up as Roche acquires 89bio for up to $3.5B

2026-02-18

The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…

RRoche

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

2026-02-17

Roche (RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. (ETNB) for $3.5 billion in a…

RRoche

2026-02-15

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and…

RRoche

2026-02-12

Under the agreement, swiss Roche AG will pay US$14.50 per share in cash, equal to an equity value…

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

Roche poised to buy MASH drug developer 89bio for $3.5bn

Roche acquires 89bio for US$3.5bn